About The Study: In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with lower all-cause mortality compared with dipeptidyl peptidase-4 inhibitor (DPP4i) use, with no significant difference relative to sodium-glucose cotransporter-2 inhibitor. The survival benefit over DPP4i persisted across age, sex, non-Hispanic white race, obesity status, and several cancer types (colorectal, lung, and breast).
Corresponding Author: To contact the corresponding author, Jingchuan Guo, MD, PhD, email guoj1@ufl.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.21887)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.21887?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071825
About JAMA Network Open : JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open